Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin appoints Robert Plenge to board, expanding it to eleven members

Neutral Impact 2 of 5 leadership Written later

BioMarin's board increased its size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent non-employee director effective September 10, 2026. Dr. Plenge also joins the board's Science and Technology Committee, and his director pay includes a restricted stock unit grant valued at $400,000.

Key points

  • Board expanded from ten to eleven members; Dr. Plenge appointed effective September 10, 2026
  • Dr. Plenge joins the Science and Technology Committee
  • Restricted stock unit grant valued at $400,000, vesting on the date immediately before the next annual meeting
  • Company intends to sign a standard indemnification agreement with Dr. Plenge

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECSep 14, 2026, 9:26 AM ET
Accession number0001628280-26-061717

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.